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ABSTRACT 
The pharmacology of novel psychoactive substances is mostly unknown. We evaluated the 
transporter and receptor interaction profiles of a series of para-(4)-substituted amphetamines 
and pyrovalerone cathinones. We tested the potency of these compounds to inhibit the 
norepinephrine (NE), dopamine (DA), and serotonin (5-HT) transporters (NET, DAT, and 
SERT, respectively) using human embryonic kidney 293 cells that express the respective 
human transporters. We also tested the substance-induced efflux of NE, DA, and 5-HT from 
monoamine-loaded cells, binding affinities to monoamine receptors, and 5-HT2B receptor 
activation. Para-(4)-substituted amphetamines, including 4-methylmethcathinone 
(mephedrone), 4-ethylmethcathinone, 4-fluoroamphetamine, 4-fluoromethamphetamine, 4-
fluoromethcatinone (flephedrone), and 4-bromomethcathinone, were relatively more 
serotonergic (lower DAT:SERT ratio) compared with their analogs amphetamine, 
methamphetamine, and methcathinone. The 4-methyl, 4-ethyl, and 4-bromo groups resulted 
in enhanced serotonergic properties compared with the 4-fluoro group. The para-substituted 
amphetamines released NE and DA. 4-Fluoramphetamine, 4-flouromethamphetamine, 4-
methylmethcathinone, and 4-ethylmethcathinone also released 5-HT similarly to 3,4-
methylenedioxymethamphetamine. The pyrovalerone cathinones 3,4-
methylenedioxypyrovalerone, pyrovalerone, α-pyrrolidinovalerophenone, 3,4-
methylenedioxy-α-pyrrolidinopropiophenone, and 3,4-methylenedioxy-α-
pyrrolidinobutiophenone potently inhibited the NET and DAT but not the SERT. Naphyrone 
was the only pyrovalerone that also inhibited the SERT. The pyrovalerone cathinones did not 
release monoamines. Most of the para-substituted amphetamines exhibited affinity for the 5-
HT2A receptor but no relevant activation of the 5-HT2B receptor. All of the cathinones 
exhibited reduced trace amine receptor 1 binding compared with the non-β-keto-
amphetamines. In conclusion, para-substituted amphetamines exhibited enhanced direct and 
indirect serotonergic agonist properties and are likely associated with more MDMA-like 
effects. The pharmacological profile of the pyrovalerone cathinones predicts pronounced 
stimulant effects and high abuse liability. 
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1. Introduction 
Novel psychoactive substances (“designer drugs”) are newly misused psychotropic 
drugs that may pose a threat to public health that is comparable to previously listed drugs of 
abuse. Novel psychoactive substances are typically sold through the Internet (i.e., “Internet 
drugs”) and misbranded as “research chemicals,” “bath salts,”, and “plant food” and labeled 
“not for human consumption.” The substances are typically chemically slightly different from 
already scheduled drugs to circumvent regulations and are therefore also termed “legal 
highs.” In the last few years, we have seen an unprecedented growth in the number of new 
psychoactive substances on the illicit drug market. More than 300 novel substances have been 
detected since 2005 (European Monitoring Center for Drugs and Drug Addiction, 2014a). 
Currently, more than one new substance is identified in one of the EU countries every week 
(European Monitoring Center for Drugs and Drug Addiction, 2014a). In most cases, 
pharmacological data are not available for the newly misused substances. Many novel 
psychoactive substances are amphetamine derivatives that can be expected to interact with the 
norepinephrine (NE), dopamine (DA), and serotonin (5-hydroxytryptamine [5-HT]) 
transporters (NET, DAT, and SERT, respectively) to inhibit monoamine transport or induce 
transporter-mediated monoamine release. However, chemical substitutions at the 
amphetamine core structure may significantly alter the absolute or relative potency of these 
newly designed substances at the NET and DAT relative to the SERT (Baumann et al., 2012; 
Blough et al., 2014; Cozzi et al., 2013; Eshleman et al., 2013; Iversen et al., 2013; Simmler et 
al., 2013; Simmler et al., 2014a; Simmler et al., 2014b). Consequently, more noradrenergic 
and dopaminergic substances may have greater sympathomimetic and reinforcing properties 
(Simmler et al., 2013). Conversely, more serotonergic substances are likely associated with 
more MDMA-like properties, including empathogenic effects, serotonin syndrome, and 
hyperpyrexia (Simmler et al., 2013; Simmler et al., 2014a). Additionally, novel 
amphetamines may directly activate monoamine receptors. Characterizing the primary 
pharmacodynamic properties of novel designer amphetamines in vitro provides a basis for 
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further preclinical studies and the evaluation of potential clinical effects, abuse potential, and 
acute toxicity of these novel substances. Such data are useful for clinical toxicologists and 
regulatory agencies for scheduling purposes. Therefore, the aim of the present study was to 
determine the effects of a series of para-(4)-substituted amphetamines and of a series of 
pyrovalerone cathinones on monoamine uptake and release and interactions with various 
monoamine receptors. 
Para-(4)-phenyl-substituted amphetamines, which have emerged in recent years, 
include 4-methylmethcathinone (mephedrone) and 4-ethylmethcathinone and particularly 
several para-halogenated compounds, including 4-fluoroamphetamine, 4-
fluoromethamphetamine, 4-fluoromethcatinone (flephedrone), and 4-bromomethcathinone. 4-
Methylmethcathinone has been the most popular and still is a very commonly misused 
cathinone in the EU (Elliott and Evans, 2014; Helander et al., 2014; Rust et al., 2012; 
Winstock et al., 2011). 4-Ethylmethcatinone was detected in 2011 in the EU (European 
Monitoring Center for Drugs and Drug Addiction, 2011), and its use is discussed in Internet 
user forums. Similarly, the use of 4-bromomethcathinone is also discussed in user forums, but 
no scientific data are available. 4-Fluoroamphetamine appeared in 2007 in the EU, followed 
later by 4-fluoromethamphetamine and 4-fluoroephedrine. 4-Fluoroephedrine may serve as a 
precursor for the synthesis of 4-fluoromethamphetamine. 4-Fluoroamphetamine and 4-
fluoromethamphetamine have also been detected in patients with acute toxicity associated 
with novel psychoactive substances and forensic cases (Helander et al., 2014; Johansen and 
Hansen, 2012; Rohrich et al., 2012; Rust et al., 2012). Users report that the subjective effects 
of 4-methlylmethcathinone (Carhart-Harris et al., 2011) and 4-fluoroamphetamine (Erowid, 
2014) are comparable to those of MDMA. Pharmacological information is available only for 
some of these novel substances, including 4-methylmethcatinone (Baumann et al., 2012; 
Eshleman et al., 2013; Simmler et al., 2013), 4-fluoroamphetamine (Marona-Lewicka et al., 
1995), and 4-fluoromethcathinone (Eshleman et al., 2013; Simmler et al., 2013). Because 4-
fluoroamphetamine and MDMA are relatively more serotonergic than amphetamine and 
methamphetamine (Marona-Lewicka et al., 1995; Simmler et al., 2013), we hypothesized that 
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a substitution at the 4-position as a characteristic of these novel para-substituted substances 
would also result in a shift toward more serotonergic than dopaminergic pharmacology. Thus, 
such para-substituted substances may also be designed to mimic the effects of MDMA. 
Pyrovalerone cathinones include 3,4,-methylenedioxypyrovalerone (MDPV), 
pyrovalerone, α-pyrrolidinovalerophenone (α-PVP), naphyrone, 3,4-methylenedioxy-α-
pyrrolidinopropiophenone (MDPPP), 3,4-methylenedioxy-α-pyrrolidinobutiophenone 
(MDPBP), α-pyrrolidinopropiophenone (α-PPP), and α-pyrrolidinobutiophenone (α-PBP). All 
of these cathinones are characterized by a pyrrolidine ring structure, making them different 
structurally and possibly also pharmacologically from other synthetic cathinones (Marusich et 
al., 2014; Simmler et al., 2013). Among the pyrovalerone cathinones, MDPV is currently the 
most widely detected and used, both in the EU (European Monitoring Center for Drugs and 
Drug Addiction, 2014b; Helander et al., 2014; Zuba and Byrska, 2013) and US (Leffler et al., 
2014; Marinetti and Antonides, 2013; Spiller et al., 2011). In fact, MDPV has become the 
most frequently detected and used of all cathinones (“bath salts”) in some EU countries 
(Helander et al., 2014; Zuba and Byrska, 2013) and the US (Leffler et al., 2014). More 
recently, a second generation of MDPV-like cathinones, including α-PVP, MDPPP, and 
MDPBP, has been detected and/or used in several EU countries (Eiden et al., 2013; Helander 
et al., 2014; Westphal et al., 2011; Zuba and Byrska, 2013) and the US (Elliott and Evans, 
2014; Smollin et al., 2011; Thornton et al., 2012). MDPV has been associated with severe 
clinical toxicity (Spiller et al., 2011) and a high potential for addiction (Aarde et al., 2013). 
Similarly, α-PVP has recently been associated with cases of severe acute psychosis and 
cardiac arrest (Eiden et al., 2013). Pharmacologically, both MDPV and α-PVP are very potent 
inhibitors of the NET and DAT but not SERT (Baumann et al., 2013; Marusich et al., 2014; 
Meltzer et al., 2006; Simmler et al., 2013). Of the second generation MDPV analogs, α-PPP 
and α-PBP also inhibit the NET and DAT similarly to MDPV (Marusich et al., 2014), but no 
data are available on MDPBP and MDPPP. We hypothesized that these and other cathinones 
with a pyrovalerone structure would inhibit the NET and DAT but not SERT, similar to 
MDPV (Marusich et al., 2014; Meltzer et al., 2006; Simmler et al., 2013). Naphyrone also 
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potently inhibits the SERT, unlike other pyrovalerone cathinones, and this exemplifies the 
necessity to pharmacologically assess each substance individually to avoid drawing false 
conclusions from structural relationships with previously assessed analogs. We predicted that 
these pyrovalerone cathinones are distinct from other cathinones, in which they are pure 
uptake inhibitors and do not act as substrate releasers as previously shown for MDPV 
(Baumann et al., 2013; Simmler et al., 2013). 
We tested whether the substances inhibit the human NET, DAT, and SERT. We also 
determined the transporter-mediated release of NE, DA, and 5-HT and characterized the 
binding affinities of the compounds for monoamine transporters, 1- and 2-adrenergic 
receptors, dopamine D1-D3 receptors, serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors, the 
histamine H1 receptor, and trace amine-associated receptor 1 (TAAR1). For example, 5-HT2A 
receptors mediate the effects of hallucinogens (Nichols, 2004) and TAAR1 play a role in the 
addictive properties of psychoactive substances (Pei et al., 2014). Furthermore, some novel 
psychoactive substances have been reported to bind to the serotonin 5-HT2B receptor (Iversen 
et al., 2013), which has been implicated in endocardial fibrosis induced by serotonergic 
substances. Therefore, we also tested functional activity at the 5-HT2B receptor. 
Some of the substances, including MDMA, amphetamine, methamphetamine, 
methcathinone, mephedrone, flephedrone, MDPV, naphyrone, and pyrovalerone, have 
previously been characterized using the same assays as those used in the present study 
(Simmler et al., 2013), but we retested them herein because of their structural similarity to the 
other substances that were evaluated, to our knowledge, for the first time. 
 
2. Methods 
2.1. Drugs 
 MDMA, amphetamine, methamphetamine, methcathinone, 4-methylmethcathinone, 
4-fluoromethcathione, 4-fluoroamphetamine, 4-fluoroephedrine, ephedrine, MDPBP, 
MDPPP, MDPV, pyrovalerone, and α-PVP were purchased from Lipomed (Arlesheim, 
Switzerland). 4-Fluoromethamphetamine, 4-etylmethcathinone, and 4-bromomethcathinone 
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were purchased from Cayman Chemicals (Ann Arbor, MI, USA). Naphyrone was synthesized 
as previously described (Simmler et al., 2013). All of the drugs were obtained as racemic 
hydrochloride salts, with the exception of ephedrine, amphetamine, and methamphetamine, 
for which the (-)-enantiomer was used. Purity was at least 98% for all of the substances. 
Radiochemicals (tritium isotopes) were obtained from Anawa (Wangen, Switzerland) or 
Perkin Elmer (Schwerzenbach, Switzerland), with the exception of [
3
H]RO5166017, which 
was synthesized at Roche (Basel, Switzerland). 
 
2.2. Monoamine uptake transport inhibition 
 Inhibition of the NET, SERT, and DAT was assessed in human embryonic kidney 
293 (HEK 293) cells that stably expressed the human NET, SERT, and DAT (Tatsumi et al., 
1997) as previously described (Hysek et al., 2012). Cultured cells were detached and 
resuspended in uptake buffer. We incubated the cells with various concentrations of the test 
compounds and the vehicle control for 10 min and then added [
3
H]DA, [
3
H]NE, and [
3
H]5-
HT (5 nM final concentration) to initiate uptake transport of the labeled monoamines at room 
temperature. Uptake was stopped after 10 min by separation of the cells from the buffer by 
rapid high-speed centrifugation through silicone oil (Hysek et al., 2012). The uptake times 
were based on previous kinetic evaluations that showed that uptake is complete after 5 min 
(Hysek et al., 2012). The centrifugation tubes were frozen in liquid nitrogen and cut to 
separate the cell pellet from the silicone oil and assay buffer layers. The cell pellet was then 
lysed. Scintillation fluid was added, and radioactivity was counted on a beta-counter. 
Nonspecific uptake was determined for each experiment in the presence of 10 M fluoxetine 
for SERT cells, 10 M nisoxetine for NET cells, and 10 M mazindol for DAT cells and 
subtracted from the total counts to yield specific uptake (100%). Nonspecific uptake was < 
15% of total uptake. The data were fit by non-linear regression to variable-slope sigmoidal 
dose-response curves, and IC50 values were calculated using Prism (GraphPad, San Diego, 
CA, USA). DAT:SERT inhibition ratios were calculated as 1/DAT IC50:1/SERT IC50. The 
  9 
DAT:SERT inhibition ratio is useful for predicting the characteristics of the psychoactive 
effects of novel psychoactive substances (Baumann et al., 2011; Simmler et al., 2013; Wee et 
al., 2005). Higher relative potency at the DAT may indicate a higher abuse potential, whereas 
relatively increased activity of the 5-HT system is linked to a reduction of abuse potential and 
more MDMA-like psychotropic effects (Wee et al., 2005). Stimulant amphetamines, such as 
methamphetamine, have a DAT:SERT inhibition ratio > 10, whereas MDMA and other 
substances with MDMA-like psychotropic effects have a DAT:SERT inhibition ratio close to 
0.1 (Baumann et al., 2012; Simmler et al., 2013; Simmler et al., 2014a; Simmler et al., 
2014b). 
 
2.3. Transporter-mediated monoamine release 
 We studied the effects of 100 µM of the test compounds on transporter-mediated NE, 
5-HT, and DA efflux in HEK 293 cells that overexpressed the respective human monoamine 
transporter as previously reported in detail (Simmler et al., 2013). Briefly, we preloaded the 
cells by incubating SERT cells with 10 nM [
3
H]5-HT, DAT cells with 10 nM [
3
H]DA and 1 
µM unlabeled DA, and NET cells with 10 nM [
3
H]NE and 10 µM unlabeled NE for 20 min. 
The cells were then washed twice, and release was induced by adding 1000 µl of release 
buffer that contained the test compounds at concentrations of 100 µM. We incubated the 
SERT and DAT cells for 15 min and NET cells for 45 min at 37°C with shaking at 300 
rotations per minute on a rotary shaker. The release times were based on kinetic evaluation of 
the release-over-time curves for MDMA. After 15 min for [
3
H]5-HT and [
3
H]DA and 45 min 
for [
3
H]NE, a sufficient amount of radioactivity was released to allow for comparisons with 
the control conditions. We then stopped release by removing the buffer and gently washing 
the cells twice with cold buffer. We quantified the radioactivity that remained in the cells. 
Nonspecific “pseudo-efflux,” which arises from nonspecific substrate release and subsequent 
reuptake inhibition (Scholze et al., 2000), was assessed for each experiment using the 
transporter inhibitors nisoxetine (NET cells), citalopram (SERT cells), and mazindol (DAT 
cells) at 10 µM as negative control conditions. We then used analysis of variance followed by 
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the Least Significant Difference test to compare substance-induced monoamine release with 
nisoxetine, citalopram, and mazindol as negative controls. Substances that induced 
significantly higher monoamine efflux at 100 µM compared with the respective transporter 
inhibitors, which induced slight nonspecific release, were considered monoamine releasers. 
 
2.4. Radioligand binding assays 
 The radioligand binding assays were performed as described previously (Hysek et al., 
2012; Revel et al., 2011; Simmler et al., 2013). Briefly, membrane preparations of HEK 293 
cells (Invitrogen, Zug, Switzerland) that overexpress the respective transporters (Tatsumi et 
al., 1997) or receptors (human genes plus TAAR1 rat and mouse genes; Revel et al., 2011) 
were incubated with the radiolabeled selective ligands at concentrations equal to Kd, and 
ligand displacement by the compounds was measured. Specific binding of the radioligand to 
the target receptor was defined as the difference between the total binding and nonspecific 
binding determined in the presence of selected competitors in excess. The following 
radioligands and competitors, respectively, were used: N-methyl-[
3
H]-nisoxetine and 
indatraline (NET), [
3
H]citalopram and indatraline (SERT), [
3
H]WIN35,428 and indatraline 
(DAT), [
3
H]8-hydroxy-2-(di-n-propylamino)tetralin and indatraline (5-HT1A receptor), 
[
3
H]ketanserin and spiperone (5-HT2A receptor), [
3
H]mesulergine and mianserin (5-HT2C 
receptor), [
3
H]prazosin and risperidone (1 adrenergic receptor), [
3
H]rauwolscine and 
phentolamine (2 adrenergic receptor), [
3
H]SCH 23390 and butaclamol (D1 receptor), 
[
3
H]spiperone and spiperone (D2 and D3 receptors), [
3
H]pyrilamine and clozapine 
(histaminergic H1 receptor), and [
3
H]RO5166017 and RO5166017 (TAAR1). IC50 values were 
determined by calculating nonlinear regression curves for a one-site model using three to five 
independent 10-point concentration-response curves for each compound. Ki (affinity) values, 
which correspond to the dissociation constants, were determined using the Cheng-Prusoff 
equation. As indicated in Table 2, previously published binding affinity data for some of the 
substances are included for comparative purposes (Simmler et al., 2013). 
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2.5. Functional serotonin 5-HT2B receptor activity 
 The 5-HT2B receptor functional assay was performed as previously described (Jensen 
et al., 2008). Briefly, human 5-HT2B receptor-expressing HEK 293 cells were incubated at 
37ºC in 96-well plates coated with poly-D-lysine. The growth medium was removed by snap 
inversion, and 100 µl of Fluo-4 solution (calcium indicator; Molecular Probes) was added. 
The plates were incubated for 45 min at 31ºC. The Fluo-4 solution was removed by snap 
inversion, and 100 µl of Fluo-4 solution was added for the second time. The cells were then 
incubated for another 45 min at 31ºC. Immediately before testing, the cells were washed with 
HBSS (Gibco) and 20 mM HEPES (assay buffer; Gibco) using an EMBLA cell washer, and 
100 µl assay buffer was added. The plate was placed in a fluorescence imaging plate reader 
(FLIPR), and 25 µl of the test substances diluted in assay buffer was added on line. The 
increase in fluorescence was then measured. EC50 values were derived from the concentration-
response curves using nonlinear regression. Efficacy (maximal activity) is expressed relative 
to the activity of 5-HT, which was used as a control set to 100%. 
 
2.6. Cytotoxicity 
 Cell membrane integrity during uptake and release testing was verified after 4 h 
treatment with each of the drugs (100 μM) using the ToxiLight BioAssay (Lonza, Basel, 
Switzerland). 
 
3. Results 
3.1. Monoamine uptake transporter inhibition 
 The monoamine transporter inhibition profiles are shown Fig. 2, and the 
corresponding IC50 values and DAT:SERT inhibition ratios are listed in Table 1. In all cases, 
the para-(4) substitution (Fig. 1A) reduced the potency of the amphetamines to inhibit both 
the NET and DAT compared with the non-para-(4)-substituted amphetamines (Table 1). In 
contrast, the potency to inhibit the SERT increased for all of the substituted amphetamines, 
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with the exception of 4-fluoromethcathinone compared with methcathinone (Table 1). As a 
result, the para-substituted substances were all relatively more serotonergic than 
dopaminergic compared with their parent compounds, reflected by their lower DAT:SERT 
inhibition ratios (Table 1). This was also evident for 4-fluoromethcathinone and 
methcathinone, despite equal SERT inhibition potencies. In the case of 4-fluoroephedrine, 4-
methylmethcathinone, 4-ethylmethcathinone, and 4-bromomethcathinones, the para 
substitution left-shifted the SERT inhibition curves over the DAT inhibition curves 
(DAT:SERT inhibition ratios < 1), resulting in monoamine transporter inhibition profiles that 
were more similar to MDMA and less similar to the parent compounds (methcathinone and 
ephedrine; Fig. 2). In contrast, all of the pyrovalerone cathinones (Fig. 1B) were very potent 
catecholamine transporter (NET and DAT) inhibitors with very low serotonergic activity, 
reflected by very high DAT:SERT inhibition ratios (Table 1). One exception was naphyrone, 
which also inhibited the SERT at submicromolar concentrations. The 3,4-methylene ring 
substitution that is found in MDMA and MDPV increased serotonergic activity compared 
with the non-substituted compounds methamphetamine and α-PVP, respectively. Similarly, 
para-methylation in pyrovalerone increased the serotonergic property of the compound 
compared with α-PVP. However, in the case of the pyrovalerones (MDPV and pyrovalerone), 
SERT inhibition potency was very low, even in the presence of these substitutions. In fact, all 
of the pyrovalerone cathinones (Fig. 1B) did not appear to interact with the SERT at 
submicromolar concentrations, with the exception of naphyrone. 
 
3.2. Transporter-mediated monoamine release 
 Monoamine release is shown in Fig. 4. All of the para-substituted amphetamine 
derivatives released NE and DA similarly to their non-substituted classic analogs 
amphetamine, methamphetamine, and methcathinone. Additionally, 4-fluoramphetamine, 4-
flouromethamphetamine, 4-methylmethcathinone, 4-ethylmethcathinone, amphetamine, and 
methamphetamine significantly released 5-HT similarly to the classic 5-HT releaser MDMA. 
4-Fluoromethcathinone, 4-bromomethcathinone, methcathinone, and ephedrine only released 
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catecholamines and not 5-HT, whereas 5-fluoroephedrine released only NE. The 
pyrovalerone cathinones did not release monoamines (Fig. 4) and thus acted as pure and 
potent uptake inhibitors (Table 1). 
 
3.3. Binding affinities 
 The monoamine transporter and receptor binding affinities are shown in Tables 2 and 
3. The pyrovalerone cathinones exhibited high affinity for the DAT and mostly also for the 
NET, consistent with their high DAT and NET blocking potency (Table 1). Most of the para-
substituted amphetamines exhibited affinity for the serotonin 5-HT2A receptor in the low 
micromolar range, similar to MDMA and dissimilar to amphetamine and methamphetamine 
(Table 3). The cathinones (β-keto-amphetamines) showed lower binding affinity for TAAR1 
compared with the non-β-keto-amphetamines (Table 2). 
 
3.4. Functional activity at serotonin 5-HT2B receptors 
 None of the substances tested exhibited relevant activation of the 5-HT2B receptor 
(Table 3). Amphetamine was the most potent activator with an IC50 of only 9.7 μM. However, 
there was only very low efficacy of 9%.    
 
3.5. Cytotoxicity 
 None of the drugs showed cytotoxicity at the highest concentration tested in the 
functional assays. 
 
4. Discussion 
 The goal of the present study was to describe the mechanism of action of two series 
of novel psychoactive substances: para-(4)-substituted (mostly halogenated) amphetamines 
and pyrovalerone cathinones. All of the para-(4)-substituted amphetamines evaluated in this 
study exhibited more serotonergic properties than their non-substituted amphetamine analogs. 
In particular, 4-bromomethcatinone, 4-ethylmethcathinone, and 4-methylmethcathinone were 
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more potent SERT inhibitors than DAT inhibitors, similar to MDMA. These findings are 
consistent with previous studies that reported an increase in serotonergic potency in para-ring-
substituted amphetamines or phenethylamines (Baumann et al., 2012; Eshleman et al., 2013; 
Simmler et al., 2013). Para-methylation (as in 4-methylmethcathinone) reduced the potency 
of DAT and increased the potency of SERT inhibition compared with methcathinone, 
consistent with previous studies (Eshleman et al., 2013; Simmler et al., 2013). Similarly, the 
para-methylation of amphetamine has previously been shown to result in reduced DAT 
inhibition and increased SERT inhibition (Wee et al., 2005). The para-flourination of 
ephedrine, amphetamine, and methamphetamine resulted in relatively more serotonergic 
properties, reflected by lower DAT:SERT inhibition ratios compared with the non-substituted 
analogs in the present study, confirming data on 4-fluoroamphetamine in rat brain 
synaptosomes (Marona-Lewicka et al., 1995; Wee et al., 2005) and 4-flouromethcathinone in 
human cell assays (Eshleman et al., 2013; Simmler et al., 2013). The presence of an ethyl or 
methyl group in the para position resulted in more pronounced serotonergic properties 
compared with a fluoro group, consistent with previous data on 4-methcathinone and 
fluoromethcathinone vs. cathinone (Simmler et al., 2013) and 4-methylamphetamine and 4-
fluoroamphetamine vs. amphetamine (Wee et al., 2005). With regard to haloamphetamines, 
para substitution with fluoride only moderately increased the relative serotonergic properties 
(DAT:SERT inhibition ratio) of several compounds in the present study (5- to 15-fold), 
whereas bromide was more effective (48-fold) and close to chloride (64-fold; Marona-
Lewicka et al., 1995) but still less effective than iodine (548-fold; Marona-Lewicka et al., 
1995). Finally, other para-substituted amphetamines, including 4-methylthioamphetamine, 
para-methoxyamphetamine, para-methoxymethamphetamine, methedrone, and 4-
trifluoromethylmethcathinone, have previously been shown to preferentially interact with the 
SERT and NET over the DAT (Cozzi et al., 2013; Simmler et al., 2014a). The entactogenic 
effects of the popular recreational drug MDMA depend on its serotonergic effects (Hysek et 
al., 2012). Consequently, substances that predominantly increase 5-HT can be expected to 
produce MDMA-like subjective effects. Additionally, the serotonergic properties of these 
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substances likely increase the risk for serotonergic toxicity, including serotonin syndrome and 
hyperthermia (Liechti et al., 2005; Simmler et al., 2011). In behavioral drug discrimination 
studies, 4-fluoroamphetamine, which is only moderately more serotonergic than 
amphetamine, is similar to amphetamine (Marona-Lewicka et al., 1995). In contrast, 4-
chloroamphetamine and 4-iodoamphetamine, which are more serotonergic (Marona-Lewicka 
et al., 1995), were behaviorally similar to MDMA-like drugs (Marona-Lewicka et al., 1995). 
4-Methylmethcathinone exhibited a DAT:SERT inhibition ratio more similar to MDMA than 
to amphetamine in the present study but was more dopaminergic in other in vitro studies 
(Eshleman et al., 2013; Iversen et al., 2013; Simmler et al., 2013). In vivo, mephedrone has 
been shown to increase DA similarly to amphetamine (Kehr et al., 2011) and 5-HT similarly 
to MDMA (Baumann et al., 2012; Kehr et al., 2011). Behaviorally, mephedrone was similar 
to MDMA (Baumann et al., 2012). The subjective effects of 4-methylmethcathinone are also 
reported to be similar to MDMA (Carhart-Harris et al., 2011) but also to cocaine (Winstock et 
al., 2011). Thus, mephedrone appears to exhibit both empathogenic and stimulant properties. 
In the present study, we also characterized the widely used cathinone MDPV, its analogs 
pyrovalerone and α-PVP, and two novel and similar compounds, MDPBP and MDPPP. These 
pyrovalerone cathinones all potently inhibited both the NET and DAT, confirming previous 
studies with MDPV (Baumann et al., 2013; Eshleman et al., 2013; Meltzer et al., 2006; 
Simmler et al., 2013), pyrovalerone (Meltzer et al., 2006; Simmler et al., 2013), and α-PVP 
(Marusich et al., 2014; Meltzer et al., 2006). Very recently, α-PBP and α-PPP have similarly 
been shown to be selective and potent catecholamine uptake inhibitors (Marusich et al., 
2014). Additionally, none of the pyrovalerone derivatives tested in the present study released 
monoamines, as expected with regard to earlier findings with pyrovalerones (Baumann et al., 
2013; Simmler et al., 2013). The pyrovalerone cathinones, which contain a pyrrolidine ring, 
likely represent a subgroup of cathinones that are mechanistically distinct from most other 
cathinones that also release monoamines similarly to the classic amphetamines (Baumann et 
al., 2012; Eshleman et al., 2013; Simmler et al., 2013). The pyrovalerones with the longest α-
side chain, including α-PVP, MDPV, and pyrovalerone, were the most potent DAT and NET 
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inhibitors, followed by α-PBP and MDPBP and by α-PPP and MDPPP, respectively 
(Marusich et al., 2014, and the present study). As shown for the para-substituted 
amphetamines in the first series of this study, the para-(4) substitution in pyrovalerone or the 
3,4-methylenedioxy substitution in MDPV, MDPBP, and MDPPP increased the absolute and 
relative serotonergic potency of the substances compared with the non-substituted parent drug 
α-PVP in the present study or compared with α-PBP and α-PPP (Marusich et al., 2014). 
However, serotonergic activity remained low for all these substances. Interestingly, 
naphyrone was the only pyrovalerone cathinone that also potently inhibited the SERT, 
confirming previous studies (Eshleman et al., 2013; Iversen et al., 2013; Meltzer et al., 2006; 
Simmler et al., 2013). With the exception of naphyrone, a hallmark of all other pyrovalerone 
cathinones is that they very potently inhibit the DAT but not SERT. Dopamine transporter-
selective over SERT-selective amphetamines produce more stimulant and abuse-related 
effects than substances with a mixed action at the DAT and SERT (Baumann et al., 2011; 
Wee et al., 2005). Accordingly, the very high DAT:SERT inhibition ratio induced by the 
pyrovalerone cathinones predicts particularly pronounced stimulant and addictive properties 
for this class of substances. In fact, MDPV and α-PVP are considered highly addictive (Aarde 
et al., 2013; Baumann et al., 2013; Watterson et al., 2014). Additionally, intoxication with 
MDPV, naphyrone, and α-PVP is associated with pronounced agitation, prolonged insomnia, 
psychotic symptoms, tachycardia, and cardiac arrest (Derungs et al., 2011; Eiden et al., 2013;  
European Monitoring Center for Drugs and Drug Addiction, 2014b; Spiller et al., 2011). 
Similar sympathetic stimulation with wild agitation and hallucinations has also been 
described with MDPPP (Smollin et al., 2011). One feature of intoxication with pyrovalerone 
cathinones is their long duration of insomnia, which can last up to several days (Derungs et 
al., 2011; Eiden et al., 2013). The long duration of action could be linked to the high potency 
of the drugs and an increased risk of overdosing. Additionally, the pyrovalerones are all 
highly lipophilic substances with associated high brain penetration (Simmler et al., 2013) and 
a high volume of distribution, resulting in longer plasma and tissue half-lives (Derungs et al., 
2011). 
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Most para-substituted amphetamines in this series exhibited direct affinity for the 
serotonin 5-HT2A receptor. The 5-HT2A receptor mediates the hallucinogenic effects of 
hallucinogens (Nichols, 2004) and also the hallucinogen-like perceptual changes associated 
with higher doses of MDMA (Liechti et al., 2000). Accordingly, these substances act as 
indirect and direct serotonergic agonists and may induce perceptual alterations. None of the 
compounds showed relevant activity as agonists at the 5-HT2B receptor. In contrast, other 
structurally related novel psychoactive substances (benzofurans) have been shown to activate 
the 5-HT2B receptor (Iversen et al., 2013), which has been suggested to be associated with an 
increased risk of endocardial fibrosis (Iversen et al., 2013). Thus, our data do not indicate a 
risk for endocardial fibrosis for the substances tested in this series. We found that 
amphetamines consistently showed higher TAAR1 binding affinities compared with the 
cathinones and ephedrins that carry a β-keto or β-hydroxy group, respectively. Consistently, 
other cathinones did not exhibit relevant TAAR1 binding (Simmler et al., 2013; Simmler et 
al., 2014a). We also found that amphetamines not only bind to rodent receptors but also 
human TAAR1. In rodents, non--keto amphetamines inhibit their own stimulant effects via 
TAAR1 activation (Di Cara et al., 2011). The lack of this TAAR1-mediated “auto-inhibition” 
with the cathinones may contribute to more stimulant-like and addictive properties of this 
new class of novel psychoactive substances compared with traditional amphetamines 
(Simmler et al., 2013). 
A particular strength of the present study was the inclusion a relatively large number of 
substances and comprehensive characterization at many targets. Other studies typically only 
assessed monoamine uptake inhibition and not substrate release or binding affinities for other 
monoamine receptors. Additionally, in the transporter inhibition assays, we also included high 
concentrations when needed to allow for better characterization of full dose-response curves 
and determination of higher IC50 values. 
The present study also has limitations. For example, we did not investigate the effects of 
the drugs on intracellular targets, such as the vesicular monoamine transporter or monoamine 
oxidase, which are affected by amphetamines (Eshleman et al., 2013). We also focused on 
  18 
pharmacodynamics in vitro. Many additional factors, such as brain penetration, metabolism, 
and pharmacokinetics, also play a role in the clinical effects of these substances, which 
require further study in vivo. 
 
5. Conclusion 
 Para-(4)-substituted amphetamines are more serotonergic than their non-substituted 
analogs, likely resulting in more MDMA-like serotonergic subjective and acute toxic effects. 
Pyrovalerone cathinones are potent NET and DAT inhibitors that are likely associated with 
significant stimulant-type effects and toxicity and a high risk of addiction. 
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Figure Legends 
 
 
Figure 1. Chemical structures of novel psychoactive substances. A. Para-(4)-substituted 
amphetamines, 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”), and other classic 
non-para-substituted amphetamines. B. Pyrovalerone-type cathinones. 
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Figure 2. Effects of para-(4)-substituted and non-substituted amphetamines on 
monoamine transport. Monoamine uptake inhibition is presented as concentration-response 
curves for the inhibition of [
3
H]NE, [
3
H]DA, and [
3
H]5-HT into NET-, DAT-, and SERT-
transfected HEK 293 cells, respectively. The data are expressed as the mean ± SEM of 3-4 
independent experiments. The lines show the data fit by nonlinear regression. The 
corresponding IC50 values are shown in Table 1. 
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Figure 3. Effects of pyrovalerone cathinones on monoamine transport. Monoamine 
uptake inhibition is presented as concentration-response curves for the inhibition of [
3
H]NE, 
[
3
H]DA, and [
3
H]5-HT into NET-, DAT-, and SERT-transfected HEK 293 cells, respectively. 
The data are expressed as the mean ± SEM of 3-4 independent experiments. The lines show 
the data fit by nonlinear regression. The corresponding IC50 values are shown in Table 1. 
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Figure 4. Effect of all substances on monoamine release. HEK 293 cells that expressed 
NET, DAT, and SERT were loaded with [
3
H]NE, [
3
H]DA, and [
3
H]5-HT, respectively, 
washed, and incubated with a high concentration of the compounds (100 µM). All para-
substituted and non-substituted amphetamines released NE, DA, or 5-HT (substances on the 
left of the vertical dashed line). In contrast, the pyrovalerone cathinones did not release 
monoamines (substances on the right of the vertical dashed line). Monoamine release is 
expressed as the percent reduction of monoamine cell content compared with vehicle (0% = 
no release; 100% release would indicate that all of the monoamine was released from the 
cells). Non-releasing monoamine transporter blockers induce nonspecific “pseudo-efflux” 
(horizontal dashed line, open bars), which arises from substrate that diffuses out of the cells 
and from subsequent reuptake inhibition. Compounds that produced significantly more 
monoamine efflux (*p < 0.05, *p<0.01, ***p < 0.001) compared with the non-releasing 
uptake inhibitors (negative controls, open bars) nisoxetine (HEK-NET cells), mazindol 
(HEK-DAT cells), and citalopram (HEK-SERT cells) were considered monoamine releasers. 
The data are expressed as the mean ± SEM of 3-4 independent experiments. 
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Table 1. Monoamine transporter inhibition.
NET DAT SERT
DAT/SERT 
inhibition ratio
IC50 [µM] (95% CI) IC50 [µM] (95% CI) IC50 [µM] (95% CI) Ratio (95% CI)
Para-(4)-substituted amphetamines
4-Fluoroephedrine 4.5 (2.0-11) 163 (40-668) 134 (76-236) 0.8 (0.1-5.9)
4-Fluoroamphetamine 0.20 (0.14-0.28) 3.7 (2.4-5.7) 19 (11-33) 5.1 (1.9-14)
4-Fluoromethamphetamine 0.22 (0.14-0.35) 7.7 (2.5-24) 8.7 (3.8-20) 1.1 (0.2-8.0)
MDMA 0.36 (0.23-0.57) 31 (8-118) 2.0 (1.4-3.0) 0.06 (0.01-0.4)
4-Fluoromethcathinone 0.36 (0.17-0.75) 14 (7.5-24) 49 (30-80) 3.6 (1.3-11)
4-Bromomethcathinone 0.41 (0.30-0.57) 5.6 (2.7-12) 2.2 (1.7-2.8) 0.4 (0.1-1.0)
4-Ethylmethcathinone 2.5 (1.7-3.7) 31 (13-72) 4.3 (3.2-5.9) 0.14 (0.04-0.5)
4-Methylmethcathinone 0.26 (0.17-0.39) 5.7 (4.3-7.5) 2.1 (1.6-2.7) 0.4 (0.2-0.7)
non para-(4)-substituted amphetamines
Ephedrine 0.32 (0.21-0.50) 46 (27-79) 230 (72-735) 5.0 (0.9-27)
Amphetamine 0.07 (0.05-0.1) 1.3 (0.8-2.0) 45 (24-85) 35 (12-106)
Methamphetamine 0.14 (0.09-0.22) 1.1 (0.7-1.7) 18 (3-116) 17 (1.8-166)
Methcathinone 0.12 (0.09-0.15) 2.4 (1.7-3.4) 46 (30-71) 19 (8.8-42)
Pyrovalerone cathinones
MDPPP 0.97 (0.62-1.5) 0.53 (0.27-1.1) 75 (49-114) 141 (45-422)
MDPBP 0.16 (0.11-0.24) 0.11 (0.07-0.16) 15 (5.4-39) 132 (34-557)
MDPV 0.04 (0.03-0.05) 0.05 (0.04-0.06) 9.6 (3.4-27) 192 (57-675)
Naphyrone 0.11 (0.05-0.27) 0.22 (0.16-0.31) 0.80 (0.6-1.2) 3.6 (1.9-7.5)
α-PVP 0.02 (0.01-0.03) 0.04 (0.01-0.1) > 100 > 1000
Pyrovalerone 0.05 (0.04-0.07) 0.07 (0.05-0.11) 23 (9.7-54) 327 (88-1080)
Values are means of three to four independent experiments and 95% confidence intervals (CI). DAT/SERT inhibition ratio = 1/DAT 
IC50 : 1/SERT IC50.
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Table 2. Monoamine transporter and receptor binding affinities. 
NET DAT SERT a1A a2A D1 D2 D3 H1 TAAR1rat TAAR1mouse TAAR1human
Para-(4)-substituted amphetamines
4-Fluoroephedrine 17.6 ± 2 27.7 ± 15 39 ± 11 > 4.9 8.4 ± 1.2 > 12 > 20 > 17 > 13 2.6 ± 1.2 17.6 ± 8 NA
4-Fluoroamphetamine 13.5 ± 2 11.0 ± 4 32 ± 9 > 4.9 4.4 ± 0.3 > 12 > 20 > 17 > 13 0.08±0.04 0.3 ± 0.1 NA
4-Fluoromethamphetamine 9.0 ± 0.6 10.8 ± 1 35 ± 12 > 4.9 2.6 ± 0.3 > 12 > 20 > 17 7.1 ± 2 0.24 ± 0.1 1.7 ± 0.9 NA
MDMA* 26.8 ± 9 8.4 ± 3 13.0 ± 2 > 6 15.0 ± 10 > 12 25 ± 13 > 17 > 13 0.37 ± 0.1 2.4 ± 1 14.6 ± 2
4-Fluoromethcathinone
#
> 25 12.2  ± 3 > 30 1.5  ± 0.1 > 20 > 12 > 30 > 17 > 13 5.4 ± 2 > 10 > 20
4-Bromomethcathinone 6.5 ± 1 3.6 ± 0.3 8.3 ± 2 8.2 ± 3 12.7 ± 0.2 > 12 >10 > 17 2.1 ± 0.1 1.8 ± 0.1 12.9 ± 3 NA
4-Ethylmethcathinone 16.2 ± 2 28 ± 16 17.5 ± 4 8.4 ± 3 21.1 ± 8 > 12 >10 > 17 > 13 > 20 > 20 NA
4-Methylmethcathinone
#
> 25 3.4 ± 0.8 > 30 3.5 ± 2 11.0  ± 5 > 12 > 30 > 9 > 13 4.3 ± 2 > 10 > 20
Non para-(4)-substituted amphetamines
Ephedrine > 30 > 30 > 30 > 12 4.1 ± 0.5 > 12 > 25 > 17 > 13 3.7±0.9 > 14.6 NA
Amphetamine
#
1.0 ± 0.6 5.7 ± 4 > 25 > 6 2.8 ± 0.8 > 12 > 30 > 17 > 13 0.23 ± 0.2 0.09 ± 0.06 0.22 ± 0.1
Methamphetamine* 3.0 ± 2 1.8 ± 0.7 24.6 ± 10 > 6 6.1 ± 2 > 12 > 30 > 17 > 13 0.35 ± 0.1 0.55 ± 0.2 1.4 ± 0.5
Methcathinone
#
1.4 ± 0.7 1.3 ± 0.2 > 30 3.9 ± 1 11.9 ± 4 > 12 > 30 > 9 > 13 4.1 ± 1 > 10 > 20
Pyrovalerone cathinones
MDPBP 1.1 ± 0.1 0.02 ± 0.002 4.1 ± 1 > 4.9 9.4 ± 2 > 12 > 20 > 17 > 13 > 20 > 20 NA
MDPPP 3.5 ± 1 0.18 ± 0.05 11.7 ± 1 > 15 13.9 ± 0.9 > 12 > 10 > 17 8.7 ± 0.6 16.1 ± 7 > 20 NA
MDPV
#
0.08 ± 0.02 0.01 ± 0.002 2.9 ± 0.1 > 6 > 20 > 12 > 30 > 9 > 13 7.2 ± 1.1 > 10 > 20
Naphyrone
#
0.18  ± 0.02 0.04  ± 0.01 0.18  ± 0.02 > 6 7.9  ± 3 > 12 > 20 > 17 2.3  ± 0.3 > 20 > 20 > 20
α-PVP 0.06 ± 0.02 0.007 ± 0.002 > 30 > 15 31.7 ± 2 > 12 > 10 > 17 > 13 16.3 ± 6 > 20 NA
Pyrovalerone
#
0.06  ± 0.01 0.03  ± 0.005 5.0  ± 0.3 > 6 > 20 > 12 > 30 > 9 10.7  ± 2 > 12 > 10 > 20
 Values are Ki  given as microM (mean ±SD); NA, not assessed
*
values are from Simmler et al. 2013 except for the TAAR1human binding
#
values are from Simmler et al. 2014 except for the TAAR1human binding
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Table 3. Serotonin5-HT2A and 5-HT2C receptor binding affinities and functional 5-HT2B receptor activity
5-HT1A 5-HT2A 5-HT2C
receptor binding 
Ki ± SEM (µM)
receptor binding 
Ki ± SEM (µM)
activation potency 
EC50 ± SEM (µM)
activation efficacy % 
maximum ± SEM
receptor binding Ki 
± SEM (µM)
Para-(4)-substituted amphetamines
4-Fluoroephedrine > 17 > 12.5 > 20 0 3.7 ± 1.1
4-Fluoroamphetamine 4.4 ± 0.8 11.3 ± 3 14.4 ± 7 58 ± 20 7.8 ± 0.7
4-Fluoromethamphetamine 5.0 ± 2 3.8 ± 0.7 > 20 0 9.5 ± 5.0
MDMA* 12.2 ± 1 5.9 ± 3 > 20 0 > 13
4-Fluoromethcathinone
#
> 20 1.4  ± 0.6 > 20 0 > 13
4-Bromomethcathinone > 20 3.3 ± 0.6 > 20 0 >13
4-Ethylmethcathinone > 20 6.5 ± 0.9 > 20 0 9.6 ± 0.4
4-Methylmethcathinone
#
> 20 2.1 ± 0.7 > 20 0 > 13
Non para-(4)-substituted amphetamines
Ephedrine > 20 > 13 > 20 0 3.3 ± 0.7
Amphetamine
#
6.7 ± 1 > 13 9.7 ± 2.2 9 ± 2 > 13
Methamphetamine* 8.1 ± 1 > 13 > 20 0 > 13
Methcathinone
#
12.8  ± 4 3.0  ± 0.6 > 20 0 > 13
Pyrovalerone cathinones
MDPBP 13.0 ± 0.02 > 13 > 20 0 > 13
MDPPP 2.5 ± 0.3 7.5 ± 0.1 > 20 0 > 13
MDPV
#
10.3 ± 5 > 13 > 20 0 > 13
Naphyrone
#
6.0  ± 0.2 11.7  ± 2 >20 0 > 13
α-PVP 5.2  ± 0.1 > 13 > 20 0 > 13
Pyrovalerone
#
13.4± 2 > 13 > 20 0 > 13
 NA, not assessed; binding values are from *Simmler et al. 2013 or 
#
Simmler et al. 2014, respectively and are included for comparison. 
5-HT2B 
 
 
